Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Cognitive Remediation Therapy Within a Secure Forensic Setting

24. Juli 2017 aktualisiert von: Ken O'Reilly, Central Mental Hospital

Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients

This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.

Studienübersicht

Detaillierte Beschreibung

This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy within a secure forensic setting for patients diagnosed with schizophrenia or schizoaffective disorder.

The feasibility of the intervention will be assessed using key indicators such as rate of enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of the primary outcome measure. The effectiveness of the intervention will be assessed using the MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning (SOFAS: Social and occupational functioning assessment scale). The effect of cognitive remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will also be examined, where programme completion is a measure of attainments from participating in additional psychosocial interventions and recovery is a measure of stability of mental state.

Patient satisfaction with cognitive remediation therapy will be assessed using a consumer constructed interview developed by Rose et al (2008) and administered by a social worker not involved in the delivery of cognitive remediation.

The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of 4.6 million. CMH provides specialised care for adults who have a mental disorder and are at risk of harming themselves or others.

After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60 patients will be randomised to receive fourteen weeks of cognitive remediation versus treatment as usual. Patients who receive treatment as usual will be offered cognitive remediation upon completion of the study. Patients allocated to cognitive remediation will receive three individual sessions of cognitive remediation a week and one group session, fifty-six sessions in total The focus of the group session is to normalise cognitive difficulties that patients may be experiencing, to receive support and to help generalise gains. The primary outcome measure the MATRICS composite score and secondary outcome measures to assess real world functioning, symptoms, violence risk, programme completion and recovery will be administered at baseline, the end of treatment and at six month follow up. Secondary measures will also include feasibility outcomes and patient satisfaction with cognitive remediation therapy. All evaluators of the effectiveness measures will be blind to participant treatment condition at the time of assessment.

The cognitive remediation therapy is a principle driven intervention consisting of nine treatment principles: Principle 1 refers to relationship building, Principle 2 refers to collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6 involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies, Principle 8 involves generalisation of gains, finally Principle 9 refers to managing ambivalence. The actual therapy will involve the use of a combination on pen, paper and computerised materials to stimulate patient's cognitive capacity and to provide them with the opportunity to apply meta-cognitive strategies.

The investigators hypothesise that it is feasible to carry out a randomised controlled trial within a single centre forensic setting and that patients will report high rates of satisfaction with cognitive remediation. It is also hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance (the primary outcome measure), real world functioning, symptoms and violence risk over time relative to patients receiving treatment as usual; specifically that there will be a treatment by time interaction. Furthermore it is hypothesised that these differences will be maintained at six month follow up after the end of treatment.

In addition it is hypothesised that patients receiving cognitive remediation will show an improvement over time on the Dundrum programme completion and recovery scales compared to those receiving treatment as usual.

While meta-analytic reviews have demonstrated that cognitive remediation therapy has a beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes et al 2011), to the best of our knowledge there has been no study with forensic mental health patients. The current study will help answer whether it is feasible to deliver cognitive remediation within a forensic mental health setting and whether it is acceptable to patients. The study aims to contribute to the evidence base for psychological interventions within a forensic setting and to answer the question as to whether cognitive remediation has a beneficial effect and if it does whether this effect is maintained over time.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

65

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Dublin, Irland, D 14
        • Central Mental Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder.

Exclusion Criteria:

  • Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cognitive Remediation Therapy
Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
Andere Namen:
  • Kognitives Training
  • Kognitive Verbesserung
  • Kognitive Rehabilitation
Aktiver Komparator: Treatment as Usual
Usual care.
Keep getting usual care.
Andere Namen:
  • Standardpflege

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The MATRICS Consensus Cognitive Battery (MCCB)
Zeitfenster: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Social and Occupational Functioning Assessment Scale (SOFAS)
Zeitfenster: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
100 item rating scale for measuring real world functioning independent of symptoms
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Positive and Negative Syndrome Scale (negative and disorganized factors)
Zeitfenster: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing psychiatric symptoms associated with schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Clinical Assessment Interview for Negative Symptoms (CAINS)
Zeitfenster: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing the negative symptoms of schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Historical Clinical and Risk Management -20 (HCR-20)
Zeitfenster: Group by time interaction: changes from baseline, to 12 months
Rating scale for assessing violence risk
Group by time interaction: changes from baseline, to 12 months
Dundrum Toolkit: Programme Completion and Recovery Scales
Zeitfenster: Group by time interaction: changes from baseline to 12 months
Rating scale for assessing progress and recovery within a forensic mental health setting
Group by time interaction: changes from baseline to 12 months
Patient satisfaction.
Zeitfenster: Average 5 months.
Consumer developed interview exploring patient satisfaction with cognitive remediation.
Average 5 months.
Feasibility outcome: rate of enrolment.
Zeitfenster: 12 months.
Willingness of forensic mental health patients to participate in study.
12 months.
Feasibility outcome: rate of retention.
Zeitfenster: 12 months.
Number of patients who complete the intervention.
12 months.
Feasibility outcome: blinding.
Zeitfenster: 12 months.
Number of patients in which the blind is broken compared to number of patients in the study.
12 months.
Completion rate of primary outcome measures
Zeitfenster: 12 months.
Number of successfully completed primary outcome measures.
12 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Professor Harry G Kennedy, M.D., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
  • Studienleiter: Professor Gary Donohoe, Ph.D., Department of Psychiatry, Trinity College Dublin.
  • Hauptermittler: Dr. Ken W O'Reilly, D.Psych.Sc., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. August 2014

Primärer Abschluss (Tatsächlich)

1. Januar 2017

Studienabschluss (Tatsächlich)

1. Januar 2017

Studienanmeldedaten

Zuerst eingereicht

4. Februar 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Februar 2015

Zuerst gepostet (Schätzen)

11. Februar 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. Juli 2017

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

24. Juli 2017

Zuletzt verifiziert

1. Juli 2017

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren